| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Outline of Final Research Achievements |
In solid cancers amplified genes are potential targets of molecular therapies. In this study the 16 genes and 22 genes reportedly amplified in gastric and mammary cancers were examined by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. In gastric cancers amplification of G1-S regulatory genes (CCNE1, CCND1and CDK6) were co-amplified with ERBB2, EGFR and/or KRAS in single cancer nuclei. In breast cancers The frequencies of the amplification of four regions containing known driver oncogenes were as follows: 8p11 (ZNF703, FGFR1, ADAM9 and IKBKB), 8q24 (MYC), 11q13 (CCND1, C11ORF30), and 17q11-21 (CPD, MED1, ERBB2, CDC6, TOP2A, MAPT) exhibited amplification in 9.6%, 9.6%, 12.4%, and 12.1% of the tumors, respectively. Co-localization of the amplicon on 8p11 and the amplicon on 11q13 in single cells was frequently observed. Precise and feasible analysis of gene amplification status can be obtained using a combination of MLPA and FISH.
|
